A newly registered clinical trial is set to explore an encouraging area of diabetes research: how the body’s own residual insulin production, measured through a marker called C-peptide, might contribute to better quality of life and health outcomes for people living with insulin-treated diabetes. The study builds on years of prior research and aims to deepen scientific understanding of how preserving even small amounts of natural insulin function could be meaningfully beneficial.
The research will draw on two large groups of participants. The first involves extending the existing StartRight study, which has already followed around 1,800 adults with new-onset diabetes for a median of four years. Participants with insulin-treated diabetes will be invited to take part in additional assessments, either remotely or in person, allowing researchers to track relationships between C-peptide levels and quality of life, mental health, and healthcare use over as long as nine years from diagnosis.
The second part of the study will involve more than 2,500 participants with type 1 diabetes who have previously had C-peptide measured and agreed to be contacted for future research. From this group, roughly 200 individuals representing a range of C-peptide levels will be recruited for detailed testing. Researchers plan to compare different methods of measuring beta cell function—including practical, at-home approaches—to determine which best predicts glycaemic outcomes using continuous glucose monitoring data, as well as patient-reported wellbeing.
What makes this research particularly promising is its focus on identifying practical, patient-friendly ways to measure a biological marker that may already be quietly supporting better health in many people with diabetes. If certain C-peptide measurement methods prove strongly linked to real-world benefits, it could pave the way for more personalized diabetes care in the future—potentially helping clinicians better tailor treatment plans based on each person’s remaining natural insulin production.
By combining long-term observational data with detailed physiological testing, this study represents a thoughtful step toward better understanding the value of preserving endogenous insulin production, and could inform future strategies aimed at protecting or supporting this function in people living with diabetes. As with any ongoing research, results will take time to emerge, but the study’s scale and design offer a solid foundation for meaningful insights.
This article is for informational purposes only and is not medical advice.
Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.
Source: Clinical Trial: Benefits of Retained Insulin for Good Health
Leave a Reply